Results 281 to 290 of about 382,920 (355)

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Blood urea nitrogen as a predictor of 28-day mortality in ICU patients with multiple myeloma: A retrospective cohort study (MIMIC-IV, 2008-2019). [PDF]

Medicine (Baltimore)
Lan T, Wang X, Tu G, Cai Z, Xu L, Luo Y.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma. [PDF]

Blood Adv
Wood WA, Kumar SK, Semmel EA, James S, Schroeder MA, Chung DJ, Rosenberg A, Zonder J, Rubinstein S, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson L, Derkach A, Geyer S, Usmani SZ.   +22 more
europepmc   +1 more source

Retreatment with talquetamab and pomalidomide in triple‐class–BCMA–GPRC5D refractory myeloma

British Journal of Haematology, EarlyView.
Kian J. Rahbari, Gliceida M. Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W. Sborov, Muhamed Baljevic   +4 more
wiley   +1 more source

Durable Remission of Highly Refractory Multiple Myeloma and Therapy-Related MDS/AML After Allogeneic Hematopoietic Cell Transplantation: Reconsidering Its Role in the CAR-T Era. [PDF]

EJHaem
Kumamoto T, Yoshihara K, Samori M, Takahashi S, Yamagata F, Fujita Y, Utsunomiya N, Yoshihara S.   +7 more
europepmc   +1 more source

Elevated desmoglein‐2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high‐risk cytogenetics and a distinct gene expression profile

British Journal of Haematology, EarlyView.
Barbara J. McClure, John Toubia, Charlotte E. J. Toomes, O. Giles Best, Angelina Yong, Cindy H. Lee, Claudine S. Bonder, Chung Hoow Kok   +7 more
wiley   +1 more source

Fiber: A New Myeloma Prevention Approach with Abundant Positive Effects. [PDF]

Cancer Discov
Fairfield H, Reagan MR.
europepmc   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting. [PDF]

Biomark Res
Wang S, Kong R, Zhong G, Yang X, Zhou X.
europepmc   +1 more source